DDInter1592 DDInter259
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Docetaxel
Docetaxel {u} (Compound) resembles {v} (Compound) Cabazitaxel
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Cabazitaxel
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Rifapentine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Rifapentine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Rifapentine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Docetaxel (Compound) and Docetaxel (Compound) resembles Cabazitaxel (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound)
Rifapentine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Cabazitaxel (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Cabazitaxel (Compound)